<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - CHLOROQUINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>CHLOROQUINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#nationalFunding" data-toggle="tab">National funding/access decisions</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Active rheumatoid arthritis (administered on expert advice)</span>,
                <span class="indication">Systemic and discoid lupus erythematosus (administered on expert advice)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                150 mg daily; maximum 2.5 mg/kg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Prophylaxis of malaria</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using syrup</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults (body-weight 45 kg and above)</strong><br/>
                310 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 6 weeks&#8211;5 months (body-weight 4.5&#8211;7 kg)</strong><br/>
                50 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 6&#8211;11 months (body-weight 8&#8211;10 kg)</strong><br/>
                75 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 1&#8211;2 years (body-weight 11&#8211;14 kg)</strong><br/>
                100 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 3&#8211;4 years (body-weight 15&#8211;16.4 kg)</strong><br/>
                125 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 4&#8211;7 years (body-weight 16.5&#8211;24 kg)</strong><br/>
                150 mg once weekly, alternatively (by mouth using tablets) 155 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 8&#8211;12 years (body-weight 25&#8211;44 kg)</strong><br/>
                225 mg once weekly, alternatively (by mouth using tablets) 232.5 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
              <li class="dose child"><strong>For children 13&#8211;17 years (body-weight 45 kg and above)</strong><br/>
                310 mg once weekly, started 1 week before entering endemic area and continued for 4 weeks after leaving.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Treatment of non-falciparum malaria</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 620 mg, then 310 mg after 6&#8211;8 hours, then 310 mg for 2 days, approximate total cumulative dose of 25 mg/kg of base.</li>
              <li class="dose child"><strong>For children </strong><br/>
                Initially 10 mg/kg (max. per dose 620 mg), then 5 mg/kg after 6&#8211;8 hours (max. per dose 310 mg), then 5 mg/kg daily (max. per dose 310 mg) for 2 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication"><ph outputclass="organism"> <i>P. vivax</i> </ph> or <ph outputclass="organism"> <i>P. ovale</i> </ph> infection during pregnancy while radical cure is postponed</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                310 mg once weekly.</li>
            </ul>
          </section>
        </section>
        
        
            <section class="doseEquivalence">
                <h3>Dose equivalence and conversion</h3>
              <p>
            <b>Doses expressed as chloroquine base</b>. Chloroquine base 150&#8239;mg = chloroquine sulfate 200&#8239;mg = chloroquine phosphate 250&#8239;mg (approx).</p>
            </section>
        
            <section class="extremesOfBodyWeight">
                <h3>Doses at extremes of body-weight</h3>
              <p>In active rheumatoid arthritis and systemic and discoid lupus erythematosus, to avoid excessive dosage in obese patients, the daily maximum dose should be calculated on the basis of ideal body weight.</p>
            </section>
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <p>Benefit of use in prophylaxis and treatment in malaria outweighs risk. For rheumatoid disease, it is not necessary to withdraw an antimalarial drug during pregnancy if the disease is well controlled.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <p>Use with caution in moderate to severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Only partially excreted by the kidneys and reduction of the dose is not required for prophylaxis of malaria except in severe impairment.</p><p>For rheumatoid arthritis and lupus erythematosus, reduce dose. </p>
            </section>
        
            <section class="generalInformation">
              <p>Manufacturers advise caution.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Gastro-intestinal disturbances, headache, pruritus, rashes, skin reactions,
              </p>
              <p>
                <strong>uncommon:</strong> Convulsions, discoloration of mucous membranes, discoloration of nails, discoloration of skin, ECG changes, hair depigmentation, hair loss, keratopathy, ototoxicity, retinal damage, visual changes,
              </p>
              <p>
                <strong>rare:</strong> Acute generalised exanthematous pustulosis, agranulocytosis, angioedema, aplastic anaemia, blood disorders, bone marrow suppression, cardiomyopathy, emotional disturbances, exfoliative dermatitis, hepatic damage, hypersensitivity reactions, mental changes, myopathy, neuromyopathy, photosensitivity, psychosis, Stevens-Johnson syndrome, thrombocytopenia, urticaria,
              </p>
              <p>
                <strong>notKnown:</strong> Diffuse parenchymal lung disease, drug rash with eosinophilia and systemic symptoms, extrapyramidal symptoms (associated with use in malaria), hypotension, visual disturbances,
              </p>
        
          <h3>Specific side effects</h3>
              <p>
                <strong>notKnown:</strong> bronchospasm in children,
              </p>
        
            <section class="advice">
                <h3>Malaria prophylaxis and treatment</h3>
              <p>Serious skin reactions, ECG changes, visual effects, ototoxicity, blood disorders, mental changes, myopathies and hepatic damage are not usually associated with malaria prophylaxis or treatment.</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Chlorquine is very toxic in overdosage; overdosage is extremely hazardous and difficult to treat. Urgent advice from the National Poisons Information Service is essential. Life-threatening features include arrhythmias (which can have a very rapid onset) and convulsions (which can be intractable).</p>
            </section>
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <p>Warn travellers going to malarious areas about <b>importance</b> of avoiding mosquito bites, <b>importance</b> of taking prophylaxis regularly, and <b>importance</b> of immediate visit to doctor if ill within 1 year and <b>especially</b> within 3 months of return.</p>
            </section>
      </section>

      <section class="tab-pane" id="nationalFunding">
        <h2>National funding/access decisions</h2>

      </section>

      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
              <h3 class="specificity">In adults</h3>
              <p>Ocular toxicity is unlikely if the dose of chloroquine phosphate does not exceed 4&#8239;mg/kg daily (equivalent to chloroquine base approx. 2.5&#8239;mg/kg daily).</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            <xref format="dita" href="#PHP78608" type="bookmark" namespace="/treatment-summaries/acute-porphyrias">Acute porphyrias</xref>
          </li>
          <li>
            G6PD deficiency
          </li>
          <li>
            long-term therapy (regular ophthalmic examination recommended by manufacturers)
          </li>
          <li>
            may aggravate myasthenia gravis
          </li>
          <li>
            may exacerbate psoriasis
          </li>
          <li>
            neurological disorders, especially epilepsy (avoid for prophylaxis of malaria if history of epilepsy)
          </li>
          <li>
            severe gastro-intestinal disorders
          </li>
        </ul>
        <ul>
          <li>
              <strong>With oral use:</strong>
            elderly in adults
          </li>
        </ul>
        <ul>
          <li>
              <strong>With <ph outputclass="route">oral</ph> use in adults:</strong>
            <p>A review group convened by the Royal College of Ophthalmologists has updated guidelines for screening to prevent ocular toxicity on long-term treatment with chloroquine and hydroxychloroquine (<i>Hydroxychloroquine and Ocular Toxicity: Recommendations on Screening 2009</i>). Chloroquine should be considered (for treating chronic inflammatory conditions) <b>only</b> if other drugs have failed. All patients taking chloroquine should receive ocular examination according to a protocol arranged locally between the prescriber and the ophthalmologist.</p>
          </li>
        </ul>
      </section>


      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in adults</h3>
              <p>Manufacturers recommend regular ophthalmological examination but the evidence of practical value is unsatisfactory.</p>
            </section>
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Ophthalmic examination with long-term therapy.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <p>Chloroquine doses for the treatment and prophylaxis of malaria in BNF publications may differ from those in product literature.</p>
            </section>
      </section>








      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <p>Can be sold to the public provided it is licensed and labelled for the prophylaxis of malaria.</p>
            </section>
      </section>


      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of CHLOROQUINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        

            <div id="PHP76546"><a href="../medicinalForm/PHP76546.html" data-target="#PHP76546" data-action="load">Tablet</a></div>
            <div id="PHP76551"><a href="../medicinalForm/PHP76551.html" data-target="#PHP76551" data-action="load">Oral solution</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
